Robert Lisicki - 04 Nov 2026 Form 3 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

SEC form
3
Accepted by SEC
04 Nov 2026, 18:38:49 UTC
Prior SEC filing
03 Mar 2025
Source filing
View source filing
Filing notes and source

Key filing fact

Robert Lisicki filed Form 3 for Arcutis Biotherapeutics, Inc. (ARQT) on 04 Nov 2026.

Key facts

  • This page summarizes Robert Lisicki's Form 3 filing for Arcutis Biotherapeutics, Inc. (ARQT).
  • 0 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 04 Nov 2026, 18:38.

Change

  • Previous filing in this sequence was filed on 03 Mar 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001779614 Primary reporting owner

Lisicki Robert

Relationship
EVP, Chief Commercial Officer

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARQT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
55,000
Date
04 Nov 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARQT holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
04 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
145,000
Exercise price
$25.61
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs") that will vest as of 25% of the RSUs on each annual anniversary of August 17, 2026 (the "Vesting Commencement Date"), beginning on August 17, 2027, subject to the Reporting Person's continued service through the vesting date.

Footnote F2

The options will vest and become exercisable at the rate of 2.0833% of the shares on each monthly anniversary of August 17, 2026, (the "Vesting Commencement Date"), subject to the Reporting Person's continued service through the applicable vesting date.

SEC remarks

Exhibit List: EX-24 - Power of Attorney.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .